Immunomodulatory effects of pre- and probiotics

益生菌和益生菌的免疫调节作用

基本信息

  • 批准号:
    BB/H00470X/1
  • 负责人:
  • 金额:
    $ 69.16万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2010
  • 资助国家:
    英国
  • 起止时间:
    2010 至 无数据
  • 项目状态:
    已结题

项目摘要

The number of people aged 65 years and over is expected to rise by over 60% in the next 25 years, which presents an enormous challenge for the healthcare system. Elderly people suffer from more frequent and severe infections than younger people; influenza is particularly common in older individuals and is a major cause of death in the elderly population. Ageing dramatically affects immune function; as we age, the repertoire of cells potentially available to respond to a new pathogen shrinks and there is an accumulation of poorly functioning mature cells. This phenomenon is known as immunosenescence and partly explains the increased susceptibility for infection in older individual. Vaccination is recommended to protect the older people against influenza, but immunosenescence also reduces the efficacy of vaccination. It has been estimated that 30-50% of older adults fail to mount protective antibody responses after influenza vaccination, representing a considerable waste of resource and a false sense of security for those receiving the vaccinations. Probiotics are beneficial bacteria, which can be consumed and which have a long and safe record of use in humans. They have shown promise in the prevention or treatment of several disease states ranging from lactose intolerance, constipation and diarrhoea, alleviation of allergy and even to more chronic systemic diseases, such as cardiovascular disease and cancer. Often they are taken together with prebiotics, which are normally fermentable carbohydrates that provide a food source for the beneficial bacteria when they reach the lower gut. There is particular interest in the positive influences of pre- and probiotics in older people, who are subject to alteration in gut microflora composition as well as immunosenescence. Several studies have demonstrated beneficial effects of specific pre- and probiotics on immune function in older subjects. However, none of these studies have taken into account the age-related shift in immune cell populations. Furthermore, there is little understanding of the mechanisms underlying these effects. Despite this, probiotics have recently been proposed as prime candidates for 'anti-immunosenescence' therapy. We propose to investigate the impact of a pre- and probiotic on immune function in young and older subjects, taking into account the age-related shifts in immunity due to immunosenescence. We aim to establish biomarkers and methodology which could be exploited to establish the underpinning science behind the immunomodulatory effects of commercial pre- and probiotics. The project will involve 60 young (18-35y) and 60 older (65-85y) subjects, who will take a pre- and probiotic mixture or a placebo for a total of 8 weeks. The probiotic is not currently commercially produced, but has been demonstrated to have particular ecological fitness and anti-pathogenic effects in the gastrointestinal tract in old age. A suitable prebiotic will be selected on the basis of ability to promote optimal growth and survival of this probiotic. After 4 weeks on the treatment, the subjects will receive an influenza vaccination. Blood samples will be taken before treatment, and at 4, 6 and 8 weeks after commencement. The samples taken at 6 and 8 weeks will be used to assess the immune response to the vaccination. A wide range of immune parameters will be assessed, taking into account the age-related shifts in immune cell populations. In conjunction with the human study, a series of in vitro studies will investigate the mechanistic basis for the impact of the probiotic on immune function and will determine whether there are differential effects of the probiotic in young and older subjects at the cellular and molecular level. The overall aim of both components of the project is to determine whether older subjects derive specific additional benefit from pre- and probiotics by modulation of the impact of immunological ageing.
65岁及以上的人口数量预计将在未来25年内增加60%以上,这对医疗保健系统提出了巨大的挑战。老年人比年轻人遭受更频繁和更严重的感染;流感在老年人中特别常见,是老年人死亡的主要原因。衰老会极大地影响免疫功能;随着年龄的增长,可能对新病原体做出反应的细胞库会缩小,功能低下的成熟细胞会积累起来。这种现象被称为免疫衰老,并部分解释了老年人对感染的易感性增加。建议接种疫苗以保护老年人免受流感的侵害,但免疫衰老也会降低疫苗接种的效力。据估计,30-50%的老年人在接种流感疫苗后未能产生保护性抗体反应,这对接受疫苗接种的人来说是一种相当大的资源浪费和虚假的安全感。益生菌是有益的细菌,可以食用,并且在人类中具有长期和安全的使用记录。它们在预防或治疗乳糖不耐症、便秘和腹泻、减轻过敏甚至更慢性的全身性疾病,如心血管疾病和癌症等多种疾病方面显示出希望。它们通常与益生元一起服用,益生元通常是可发酵的碳水化合物,当它们到达下肠道时为有益细菌提供食物来源。人们特别感兴趣的是益生菌和益生菌对老年人的积极影响,老年人易受肠道微生物群组成和免疫衰老的影响。几项研究已经证明了特定益生菌和益生菌对老年受试者免疫功能的有益作用。然而,这些研究都没有考虑到免疫细胞群体中与年龄相关的变化。此外,人们对这些影响的机制知之甚少。尽管如此,益生菌最近已被提议作为“抗免疫衰老”疗法的主要候选物。我们建议研究益生菌对年轻和老年受试者免疫功能的影响,同时考虑到免疫衰老引起的免疫力年龄相关变化。我们的目标是建立生物标志物和方法,可用于建立商业益生菌和益生菌免疫调节作用背后的基础科学。该项目将涉及60名年轻(18- 35岁)和60名老年(65- 85岁)受试者,他们将服用益生菌混合物或安慰剂共8周。益生菌目前尚未商业化生产,但已被证明在老年胃肠道中具有特定的生态适应性和抗病原体作用。将基于促进该益生菌的最佳生长和存活的能力来选择合适的益生元。治疗4周后,受试者将接受流感疫苗接种。将在治疗前以及治疗开始后第4、6和8周采集血样。在第6周和第8周采集的样本将用于评估对疫苗接种的免疫应答。将评估广泛的免疫参数,同时考虑免疫细胞群中与年龄相关的变化。结合人体研究,一系列体外研究将调查益生菌对免疫功能影响的机制基础,并将确定益生菌在年轻和老年受试者中是否存在细胞和分子水平的差异效应。该项目的两个组成部分的总体目标是确定老年受试者是否通过调节免疫老化的影响从益生菌和益生菌中获得特定的额外益处。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Additional file 1: Figure S1. of Effect of a synbiotic on the response to seasonal influenza vaccination is strongly influenced by degree of immunosenescence
附加文件 1:图 S1。
  • DOI:
    10.6084/m9.figshare.c.3599351_d3
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Przemska-Kosicka A
  • 通讯作者:
    Przemska-Kosicka A
Impact of ageing and a synbiotic on the immune response to seasonal influenza vaccination; a randomised controlled trial.
  • DOI:
    10.1016/j.clnu.2017.01.011
  • 发表时间:
    2018-04
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Enani S;Przemska-Kosicka A;Childs CE;Maidens C;Dong H;Conterno L;Tuohy K;Todd S;Gosney M;Yaqoob P
  • 通讯作者:
    Yaqoob P
Impact of probiotics on the immune response to influenza vaccination is strongly influenced by ageing
益生菌对流感疫苗免疫反应的影响受到衰老的强烈影响
  • DOI:
    10.1111/nbu.12253
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    3.3
  • 作者:
    Yaqoob P
  • 通讯作者:
    Yaqoob P
Age-Related Changes in the Natural Killer Cell Response to Seasonal Influenza Vaccination Are Not Influenced by a Synbiotic: a Randomised Controlled Trial.
  • DOI:
    10.3389/fimmu.2018.00591
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    Przemska-Kosicka A;Childs CE;Maidens C;Dong H;Todd S;Gosney MA;Tuohy KM;Yaqoob P
  • 通讯作者:
    Yaqoob P
Effect of a synbiotic on the response to seasonal influenza vaccination is strongly influenced by degree of immunosenescence.
  • DOI:
    10.1186/s12979-016-0061-4
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Przemska-Kosicka A;Childs CE;Enani S;Maidens C;Dong H;Dayel IB;Tuohy K;Todd S;Gosney MA;Yaqoob P
  • 通讯作者:
    Yaqoob P
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Parveen Yaqoob其他文献

Dietary fatty acids and chylomicron synthesis and secretion.
膳食脂肪酸和乳糜微粒的合成和分泌。
  • DOI:
    10.1042/bst0320055
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    3.9
  • 作者:
    Christine M. Williams;P. Bateman;Kim G. Jackson;Parveen Yaqoob
  • 通讯作者:
    Parveen Yaqoob

Parveen Yaqoob的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Parveen Yaqoob', 18)}}的其他基金

University of Reading EPSRC ECR Equipment Bid
雷丁大学 EPSRC ECR 设备招标
  • 批准号:
    EP/S017828/1
  • 财政年份:
    2018
  • 资助金额:
    $ 69.16万
  • 项目类别:
    Research Grant
Effects of n-3 polyunsaturated fatty acids on the generation and functional activities of microparticles
n-3多不饱和脂肪酸对微粒生成及功能活性的影响
  • 批准号:
    BB/N021185/1
  • 财政年份:
    2017
  • 资助金额:
    $ 69.16万
  • 项目类别:
    Research Grant
BBSRC DRINC Training Grant 2010
BBSRC DRINC 培训补助金 2010
  • 批准号:
    BB/H531978/1
  • 财政年份:
    2010
  • 资助金额:
    $ 69.16万
  • 项目类别:
    Training Grant

相似国自然基金

Dynamic Credit Rating with Feedback Effects
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    万元
  • 项目类别:
    外国学者研究基金项目
NPM1表观重塑巨噬细胞代谢及修复表型在心肌缺血损伤中的调控作用
  • 批准号:
    82371825
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
内源性蛋白酶抑制剂SerpinA3N对缺血性脑卒中后血脑屏障的保护作用及其表达调控机制
  • 批准号:
    82371317
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
儿童期受虐经历影响成年人群幸福感:行为、神经机制与干预研究
  • 批准号:
    32371121
  • 批准年份:
    2023
  • 资助金额:
    50.00 万元
  • 项目类别:
    面上项目
水环境中新兴污染物类抗生素效应(Like-Antibiotic Effects,L-AE)作用机制研究
  • 批准号:
    21477024
  • 批准年份:
    2014
  • 资助金额:
    86.0 万元
  • 项目类别:
    面上项目
动态整体面孔认知加工的认知机制的研究
  • 批准号:
    31070908
  • 批准年份:
    2010
  • 资助金额:
    31.0 万元
  • 项目类别:
    面上项目
磁性隧道结的势垒及电极无序效应的研究
  • 批准号:
    10874076
  • 批准年份:
    2008
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目
抗抑郁剂调控细胞骨架蛋白的功能研究
  • 批准号:
    30472018
  • 批准年份:
    2004
  • 资助金额:
    16.0 万元
  • 项目类别:
    面上项目

相似海外基金

Immunomodulatory effects of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in mucosal pemphigus vulgaris
桥粒芯糖蛋白 3 嵌合自身抗体受体 T 细胞 (DSG3-CAART) 对粘膜寻常型天疱疮的免疫调节作用
  • 批准号:
    10679911
  • 财政年份:
    2023
  • 资助金额:
    $ 69.16万
  • 项目类别:
Immunomodulatory and behavioral effects of CAR T regulatory cell therapy for Alzheimer's Disease”.
CAR T 调节细胞疗法对阿尔茨海默病的免疫调节和行为影响。
  • 批准号:
    10633721
  • 财政年份:
    2023
  • 资助金额:
    $ 69.16万
  • 项目类别:
Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer
免疫调节生物材料可增强 T 细胞对三阴性乳腺癌的反应
  • 批准号:
    10699815
  • 财政年份:
    2023
  • 资助金额:
    $ 69.16万
  • 项目类别:
The Immunomodulatory Effects of Nrf2 Activation on Macrophages in the Lung Tumor Microenvironment
Nrf2 激活对肺肿瘤微环境中巨噬细胞的免疫调节作用
  • 批准号:
    10678092
  • 财政年份:
    2023
  • 资助金额:
    $ 69.16万
  • 项目类别:
Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal Cancer
新型替莫唑胺组合靶向 DNA 修复对结直肠癌的免疫调节作用
  • 批准号:
    10462786
  • 财政年份:
    2021
  • 资助金额:
    $ 69.16万
  • 项目类别:
Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal Cancer
新型替莫唑胺组合靶向 DNA 修复对结直肠癌的免疫调节作用
  • 批准号:
    10675088
  • 财政年份:
    2021
  • 资助金额:
    $ 69.16万
  • 项目类别:
Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal Cancer
新型替莫唑胺组合靶向 DNA 修复对结直肠癌的免疫调节作用
  • 批准号:
    10301255
  • 财政年份:
    2021
  • 资助金额:
    $ 69.16万
  • 项目类别:
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment
利用舒林酸和新型非 COX 抑制衍生物的免疫调节作用来治疗癌症
  • 批准号:
    10113565
  • 财政年份:
    2020
  • 资助金额:
    $ 69.16万
  • 项目类别:
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts
靶向递送免疫调节生物制剂以诱导同种异体胰岛移植物的免疫特权
  • 批准号:
    10227259
  • 财政年份:
    2020
  • 资助金额:
    $ 69.16万
  • 项目类别:
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment
利用舒林酸和新型非 COX 抑制衍生物的免疫调节作用来治疗癌症
  • 批准号:
    9917342
  • 财政年份:
    2020
  • 资助金额:
    $ 69.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了